Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2015-10-01
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and remodeling the choroidal vascularization.
This retrospective study aims to perform a quantitative analysis of retinal and CC vessel density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent eplerenone.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Half fluence photodynamic therapy
Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy
The patients underwent half fluence photodynamic therapy for 6 months
Half fluence photodynamic therapy for 6 months
Oral Eplerenone
Patients with central serous chorioretinopathy, treated by oral eplerenone
Eplerenone
The patients underwent eplerenone treatment for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eplerenone
The patients underwent eplerenone treatment for 6 months
The patients underwent half fluence photodynamic therapy for 6 months
Half fluence photodynamic therapy for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of central serous chorioretinopathy
* treatment-naïve with half-fluence photodynamic therapy or oral eplerenone
* absence of vitreoretinal and vascular retinal diseases
Exclusion Criteria
* absence of diagnosis of central serous chorioretinopathy
* previous treatment with half-fluence photodynamic therapy or oral eplerenone
* presence of concomitant vitreoretinal and vascular retinal diseases
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gilda Cennamo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilda Cennamo
Role: PRINCIPAL_INVESTIGATOR
Università Federico II
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1010/2021
Identifier Type: -
Identifier Source: org_study_id